首页> 美国卫生研究院文献>OncoTargets and therapy >miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer
【2h】

miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer

机译:miR-17-92a-1簇宿主基因(MIR17HG)在直肠癌新辅助放化疗中的评估和响应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is the gold standard for the treatment of patients with locally advanced rectal cancer (LARC). However, response is variable, and no predictive markers have been validated. The amplification of 13q31–34 seemed to distinguish between nonresponders and responders to NCRT. The miR-17-92a-1 cluster host gene (MIR17HG), which is involved in the development, progression, and aggressiveness of colorectal cancer, and the ABCC4 gene, an ATP-binding cassette transporter, are located at this region. Moreover, the transcription factor c-Myc is closely related to MIR17HG. The aim of this study was to examine the role of MIR17HG, ABCC4, and CMYC gene copy numbers (CNs) in determining response to NCRT. We analyzed DNA CN of pretherapy biopsies from 108 LARC patients and the expression of microRNA (miR)-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and miR-92a-1 in 34 biopsies. MIR17HG, CMYC, and ABCC4 gene CNs were frequently altered in pretreatment tumors, amplification being the most frequent alteration. With regard to response to therapy, 41% of responders showed MIR17HG deletion, while MIR17HG amplification was observed in 41% of nonresponders. With regard to pathological T stage (ypT), a higher percentage of ypT3–4 than ypT0–2 tumors showed MIR17HG amplification. Finally, a higher, albeit nonsignificant, variability in the expression of MIR17HG cluster members was detected in nonresponders compared to responders. No association was observed between clinical pathological parameters and ABCC4 or CMYC CN. Our data did not highlight a significant association between MIR17HG, CMYC, and ABCC4 gene CNs and response to NCRT in LARC. However, MIR17HG gene amplification would seem to be related to a lack of response. Evaluation of the expression of MIR17HG cluster members is warranted in a larger case series, together with functional studies, to evaluate the potential of this gene as a new predictive marker.
机译:新辅助放化疗(NCRT)和手术治疗是治疗局部晚期直肠癌(LARC)患者的金标准。但是,反应是可变的,并且尚未验证任何预测标记。 13q31–34的扩增似乎可以区分无反应者和对NCRT的反应者。 miR-17-92a-1簇宿主基因(MIR17HG)与大肠癌的发生,发展和侵袭有关,而ABCC4基因(一种ATP结合盒转运蛋白)位于该区域。而且,转录因子c-Myc与MIR17HG密切相关。这项研究的目的是检查MIR17HG,ABCC4和CMYC基因拷贝数(CN)在确定对NCRT反应中的作用。我们分析了108名LARC患者的治疗前活检的DNA CN和34例活检中microRNA(miR)-17,miR-18a,miR-19a,miR-19b-1,miR-20a和miR-92a-1的表达。 MIR17HG,CMYC和ABCC4基因CNs在预处理肿瘤中经常发生改变,其中扩增是最常见的改变。关于治疗的反应,有41%的反应者显示MIR17HG缺失,而在41%的无反应者中观察到MIR17HG扩增。关于病理性T期(ypT),ypT3–4的比例高于ypT0–2的肿瘤表现出MIR17HG扩增。最后,与响应者相比,在非响应者中检测到更高的MIR17HG簇成员表达差异,尽管无统计学意义。在临床病理参数与ABCC4或CMYC CN之间未发现关联。我们的数据未显示MIR17HG, CMYC ABCC4 基因CNs与LARC对NCRT的反应之间存在显着关联。但是, MIR17HG 基因扩增似乎与缺乏反应有关。在较大的病例系列中,有必要评估 MIR17HG 簇成员的表达,并进行功能研究,以评估该基因作为新的预测标记物的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号